SFX by Ex Libris Inc.

Title:	Selective activation of p53-mediated tumour suppression in high-grade tumours
Source:	Nature [0028-0836] Junttila, M R yr:2010

Basic

Full text

Full text available via Nature

Year:

Volume:

Issue:

Start Page:

Document delivery

Request document via Library/Bibliothek

Users interested in this article also expressed an interest in the following:
description	1.	Feldser, David M. "Stage-specific sensitivity to p53 restoration during lung cancer progression." Nature 468.7323 (2010): 572-575.
description	2.	Hanahan, D. "The hallmarks of cancer." Cell 100.1 (1999): 57-70.
description	3.	Paez, J Guillermo G. "EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy." Science 304.5676 (2004): 1497-1500.
description	4.	Soucek, L. "Modelling Myc inhibition as a cancer therapy." Nature 455.7213 (2008): 679-83.
description	5.	Jung, Joo Eun E. "STAT3 is a potential modulator of HIF-1-mediated VEGF expression in human renal carcinoma cells." The FASEB journal 19.10 (2005): 1296-8.
description	6.	Weinberg, Robert A. "Hallmarks of cancer: the next generation." Cell 144.5 (2011): 646-674.
description	7.	Lazebnik, Y. "What are the hallmarks of cancer?" Nature Reviews. Cancer 10.4 (2010): 232-3.
description	8.	Lynch, Thomas J J. "Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib." The New England journal of medicine 350.21 (2004): 2129-39.
description	9.	Kinzler, Kenneth W W. "Cancer genes and the pathways they control." Nature medicine 10.8 (2004): 789-99.
description	10.	Dunn, Gavin P P. "The immunobiology of cancer immunosurveillance and immunoediting." Immunity 21.2 (2004): 137-148.
description	11.	Reya, T. "Stem cells, cancer, and cancer stem cells." Nature 414.6859 (2001): 105-111.
description	12.	Luo, J. "Principles of Cancer Therapy : Oncogene and Non-oncogene Addiction." Cell 136.5 (2009): 823-837.
description	13.	LÃ³pez-OtÃn, C. "The hallmarks of aging." Cell 153.6 (2013): 1194-1217.
description	14.	Ibrahim, Ashraf E.K. J. "Molecular typing of colorectal cancer: applications in diagnosis and treatment." Diagnostic histopathology 18.2 (2012): 70-80.
description	15.	Pao, W. "EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib." Proceedings of the National Academy of Sciences of the United States of America 101.36 (2004): 13306-13311.
description	16.	Sordella, R. "Gefitinib-sensitizing EGFR mutations in lung cancer activate anti-apoptotic pathways." Science 305.5687 (2004): 1163-1167.
description	17.	Shepherd, F. "Erlotinib in previously treated non-small-cell lung cancer." New England Journal of Medicine, The 353.2 (2005): 123-132.
description	18.	Broz, Daniela K. "In vivo analysis of p53 tumor suppressor function using genetically engineered mouse models." Carcinogenesis 31.8 (2010): 1311-1318.
description	19.	Lowe, SW. "Activation of p53 by oncogenes." Endocrine-related cancer 6.1 (1999): 45-48.
description	20.	Phuoc T. Tran et al.;, Dean W W. "Combined Inactivation of MYC and K-Ras Oncogenes Reverses Tumorigenesis in Lung Adenocarcinomas and Lymphomas." PLOS One 3.5 (2008).